Covid-19 in patients with hematological and solid cancers at a Comprehensive Cancer Center in Germany.
Aged
Aged, 80 and over
Betacoronavirus
/ isolation & purification
COVID-19
Coronavirus Infections
/ complications
Female
Germany
/ epidemiology
Hematologic Neoplasms
/ epidemiology
Hospitalization
/ statistics & numerical data
Humans
Male
Middle Aged
Neoplasms
/ epidemiology
Oncology Service, Hospital
/ trends
Pandemics
Pneumonia, Viral
/ complications
Prognosis
Retrospective Studies
Risk Factors
SARS-CoV-2
Survival Rate
cancer management
epidemiology
epidemiology and prevention
viral infection
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
22
07
2020
accepted:
16
08
2020
pubmed:
16
9
2020
medline:
1
12
2020
entrez:
15
9
2020
Statut:
ppublish
Résumé
Patients with cancer are considered a high-risk group for viral pneumonia, with an increased probability of fatal outcome. Here, we investigated the clinical characteristics and outcome of patients with solid and hematological cancers and concomitant Covid-19 at a Comprehensive Cancer Center in a Covid-19 hotspot area in Germany. We performed a retrospective single center cohort study of 39 patients with hematological and solid cancers who were hospitalized at the University Hospital Freiburg for Covid-19. Using univariate and multivariate Cox regression models we compared time to severe events and overall survival to an age-matched control cohort of 39 patients with confirmed Covid-19 without a cancer diagnosis. In the cancer cohort 29 patients had a diagnosis of a solid tumor, and 10 had a hematological malignancy. In total, eight patients (21%) in the cancer and 14 patients (36%) from the noncancer cohort died during the observation period. Presence of a malignancy was not significantly associated with survival or time to occurrence of severe events. Major influences on mortality were high IL-6 levels at Covid-19 diagnosis (HR = 6.95, P = .0121) and age ≥ 65 years (HR = 6.22, P = .0156). Compared to an age-matched noncancer cohort, we did not observe an association between a cancer diagnosis and a more severe disease course or higher fatality rate in patients with Covid-19. Patients with a hematological malignancy showed a trend towards a longer duration until clinical improvement and longer hospitalization time compared to patients with a solid cancer. Cancer per se does not seem to be a confounder for dismal outcome in Covid-19.
Sections du résumé
BACKGROUND
Patients with cancer are considered a high-risk group for viral pneumonia, with an increased probability of fatal outcome. Here, we investigated the clinical characteristics and outcome of patients with solid and hematological cancers and concomitant Covid-19 at a Comprehensive Cancer Center in a Covid-19 hotspot area in Germany.
METHODS
We performed a retrospective single center cohort study of 39 patients with hematological and solid cancers who were hospitalized at the University Hospital Freiburg for Covid-19. Using univariate and multivariate Cox regression models we compared time to severe events and overall survival to an age-matched control cohort of 39 patients with confirmed Covid-19 without a cancer diagnosis.
RESULTS
In the cancer cohort 29 patients had a diagnosis of a solid tumor, and 10 had a hematological malignancy. In total, eight patients (21%) in the cancer and 14 patients (36%) from the noncancer cohort died during the observation period. Presence of a malignancy was not significantly associated with survival or time to occurrence of severe events. Major influences on mortality were high IL-6 levels at Covid-19 diagnosis (HR = 6.95, P = .0121) and age ≥ 65 years (HR = 6.22, P = .0156).
CONCLUSIONS
Compared to an age-matched noncancer cohort, we did not observe an association between a cancer diagnosis and a more severe disease course or higher fatality rate in patients with Covid-19. Patients with a hematological malignancy showed a trend towards a longer duration until clinical improvement and longer hospitalization time compared to patients with a solid cancer. Cancer per se does not seem to be a confounder for dismal outcome in Covid-19.
Identifiants
pubmed: 32931637
doi: 10.1002/cam4.3460
pmc: PMC7666742
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
8412-8422Informations de copyright
© 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Lancet. 2020 Jun 20;395(10241):1919-1926
pubmed: 32473682
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Lancet Oncol. 2009 Jun;10(6):589-97
pubmed: 19482247
Lancet Oncol. 2020 Jul;21(7):893-903
pubmed: 32479790
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
J Infect. 2020 Jun;80(6):639-645
pubmed: 32240670
Cancer Med. 2020 Nov;9(22):8412-8422
pubmed: 32931637
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
Nat Rev Immunol. 2020 Jun;20(6):363-374
pubmed: 32346093
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
J Geriatr Oncol. 2020 Jun;11(5):764-768
pubmed: 32331928
Ann Oncol. 2020 Jul;31(7):894-901
pubmed: 32224151
J Clin Invest. 2020 May 1;130(5):2620-2629
pubmed: 32217835
Cancer Discov. 2020 Jun;10(6):783-791
pubmed: 32345594
N Engl J Med. 2020 May 7;382(19):1787-1799
pubmed: 32187464
JAMA. 2020 May 12;323(18):1767-1768
pubmed: 32250388
Leukemia. 2020 Jun;34(6):1487-1494
pubmed: 32358568
J Med Virol. 2020 Apr;92(4):401-402
pubmed: 31950516
Lancet. 2020 Jun 20;395(10241):1907-1918
pubmed: 32473681
Cancer Discov. 2020 Jul;10(7):935-941
pubmed: 32357994
J Hematol Oncol. 2020 Jun 10;13(1):75
pubmed: 32522278
Lancet Oncol. 2020 Jul;21(7):904-913
pubmed: 32479787
Eur J Cancer. 2016 Nov;67:200-212
pubmed: 27681877
Clin Exp Immunol. 2004 Apr;136(1):95-103
pubmed: 15030519
Leukemia. 2020 Aug;34(8):2000-2011
pubmed: 32444866
BMJ. 2020 May 22;369:m1985
pubmed: 32444460